These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27642533)

  • 21. Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis.
    Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio MP; Wan GJ
    J Health Econ Outcomes Res; 2022; 9(1):90-100. PubMed ID: 35529249
    [No Abstract]   [Full Text] [Related]  

  • 22. [Inflammatory myopathies. Dermatomyositis, polymyositis, and inclusion body myositis].
    Selva O'Callaghan A; Trallero Araguás E
    Reumatol Clin; 2008 Sep; 4(5):197-206. PubMed ID: 21794530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory myopathies: evaluation and management.
    Greenberg SA
    Semin Neurol; 2008 Apr; 28(2):241-9. PubMed ID: 18351525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pathogenesis of polymyositis and dermatomyositis].
    Morović-Vergles J; Mitrović J
    Reumatizam; 2012; 59(2):23-6. PubMed ID: 23745450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repository corticotropin injection (H.P. Acthar gel) for the treatment of sarcoidosis-induced hypercalciuria and vitamin D dysregulation: a pilot, open label study.
    Judson MA; Modi A; Ilyas F; Yucel R
    Sarcoidosis Vasc Diffuse Lung Dis; 2018; 35(3):192-197. PubMed ID: 32476902
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study.
    Furie R; Mitrane M; Zhao E; Das M; Li D; Becker PM
    Lupus Sci Med; 2016; 3(1):e000180. PubMed ID: 27933199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dermatomyositis and polymyositis: clinical aspects and treatment].
    Hachulla E
    Ann Med Interne (Paris); 2001 Nov; 152(7):455-64. PubMed ID: 11965087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Noninfectious Retinal Vasculitis Using Subcutaneous Repository Corticotropin Injection.
    Anesi SD; Chang PY; Maleki A; Stephenson A; Montieth A; Filipowicz A; Syeda S; Asgari S; Walsh M; Metzinger JL; Foster CS
    J Ophthalmic Vis Res; 2021; 16(2):219-233. PubMed ID: 34055260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repository corticotropin for Chronic Pulmonary Sarcoidosis.
    Baughman RP; Sweiss N; Keijsers R; Birring SS; Shipley R; Saketkoo LA; Lower EE
    Lung; 2017 Jun; 195(3):313-322. PubMed ID: 28353116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis).
    Pongratz D
    J Neurol; 2006 Sep; 253 Suppl 5():V64-5. PubMed ID: 16998756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeutic strategy in inflammatory myopathies (polymyositis, dermatomyositis, overlap myositis, and immune-mediated necrotizing myopathy)].
    Tournadre A
    Rev Med Interne; 2014 Jul; 35(7):466-71. PubMed ID: 24144868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exercise effects in patients with adult idiopathic inflammatory myopathies.
    Alexanderson H
    Curr Opin Rheumatol; 2009 Mar; 21(2):158-63. PubMed ID: 19339927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of inflammatory myopathies.
    Mastaglia FL; Phillips BA; Zilko P
    Muscle Nerve; 1997 Jun; 20(6):651-64. PubMed ID: 9149071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the therapy of idiopathic inflammatory myopathies.
    Baer AN
    Curr Opin Rheumatol; 2006 May; 18(3):236-41. PubMed ID: 16582685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic advances in myositis.
    Aggarwal R; Oddis CV
    Curr Opin Rheumatol; 2012 Nov; 24(6):635-41. PubMed ID: 22955021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features.
    Khan S; Christopher-Stine L
    Rheum Dis Clin North Am; 2011 May; 37(2):143-58, v. PubMed ID: 21444016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current pharmacological treatment of idiopathic inflammatory myopathies.
    Fasano S; Alves SC; Isenberg DA
    Expert Rev Clin Pharmacol; 2016 Apr; 9(4):547-558. PubMed ID: 26708717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current diagnosis and treatment of polymyositis and dermatomyositis.
    Sasaki H; Kohsaka H
    Mod Rheumatol; 2018 Nov; 28(6):913-921. PubMed ID: 29669460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Intravenous immunoglobulins in the treatment of polymyositis and dermatomyositis].
    Cherin P
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S48-50. PubMed ID: 10896990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
    Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
    J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.